retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity First-in-Class 'Triple-G'! Retatrutide, a first-in Retatrutide—A Game Changer in Obesity

Sato, T., Shimizu, T., Fujita, H., Imai, Y., Drucker, D

GLP-1 receptors (GLP1R), which are found in pancreatic beta cells as well as other cell types, receive the GLP-1 signal, triggering the release of insulin

Most GLP-1 solutions should be clear and colourless to slightly yellow, but some products (like exenatide prolonged-release) are suspensions and appear cloudy by design

NPJ Metab Health Dis Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression

BPC-157, TB-500, and most repair-oriented peptides have no known endocrine or metabolic effects that would mechanistically interact with GLP-1 signaling

Research shows that even a 5-10% reduction in body weight can meaningfully lower osteoarthritis symptoms and joint inflammation markers in some individuals